PolyPeptide Is Said to Attract Takeover Interest From EQT, KKR

Swiss contract drugmaker PolyPeptide Group AG is attracting potential takeover interest from private equity firms including EQT AB and KKR & Co., people with knowledge of the matter said.

Advent has also been studying a possible acquisition of PolyPeptide, the people said, asking not to be identified because the information is private. Any buyout firm pursuing a take-private deal could seek to team up with its billionaire controlling shareholder, Swedish businessman Frederik Paulsen Jr., according to the people.

Shares of Zug-based PolyPeptide have risen almost 20% this year, giving the company a market value of about 1 billion ...